New Therapy Targeting Malignant B Cells
The FDA has approved a new antibody-drug conjugate to treat two types of non-Hodgkin B-cell lymphomas The U.S. Food...
Progress Against Cancer
The FDA has approved a new antibody-drug conjugate to treat two types of non-Hodgkin B-cell lymphomas The U.S. Food...
This is the first modified, donor cord blood–based stem cell therapy approved to reduce time to hematopoietic recovery and...
With the approval of new anticancer therapeutics, more treatment options become available for patients. Some therapies are new to...
A targeted therapy is now available for more patients with advanced bladder cancers The U.S. Food and Drug Administration...
The FDA has approved the monoclonal antibody retifanlimab-dlwr for some patients with Merkel cell carcinoma. The U.S. Food and...
A targeted therapy regimen was approved to treat some children with brain cancer The U.S. Food and Drug Administration...
The FDA approved abemaciclib with endocrine therapy for HR-positive, HER2-negative, early-stage breast cancer at high risk of recurrence. The...
A drug that selectively targets cancer cells was approved for the treatment of certain HR-positive breast cancers. The U.S....
The FDA approved the immune checkpoint inhibitor dostarlimab-gxly to treat advanced uterine cancer with certain mutations. The U.S. Food...
The FDA has approved the oral SERD elacestrant to treat certain patients with estrogen receptor-positive breast cancer. The U.S....